Please assess the completion status of the following clinical trial:

Trial Title: Pharmacologic Modulation of Hippocampal Activity in Psychosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria for psychosis subjects:~1. Men and women age 18 - 65.~2. Communicative in English.~3. Provide voluntary, written informed consent.~4. Physically healthy by medical history.~5. BMI \> 17.5 and \< 45.~6. Diagnosis of a psychotic disorder confirmed by Structured Clinical Interview for DSM-V (SCID) or diagnostic interview with a trained clinician.~7. Stable medication regimen over at least the past two weeks, including the use of either an oral or intramuscular administration of an antipsychotic medication.~8. For females, no longer of child-bearing potential, or agreeing to practice effective contraception during the study; and,~9. For females of child-bearing potential, must have negative urine pregnancy test at time of screening visit and before each testing day.~10. Not breastfeeding/nursing at time of screening or at any time during the study.~Inclusion criteria for healthy controls All of the above except for subjects will be psychiatrically healthy and not taking psychotropic or potentially psychoactive prescription medication.~Exclusion criteria for psychosis subjects~1. Age less than 18 or greater than 65.~2. Not communicative in English.~3. Unable to provide written informed consent.~4. Current medical or neurological illness.~5. History of severe head trauma.~6. BMI \< 17.5 or \> 45.~7. Meets criteria for diagnosis of substance or alcohol use disorder within the past month.~8. Positive urine pregnancy test at time of screening, before each testing day, or any potential concern for pregnancy at any time during the study.~9. Breastfeeding/nursing at time of screening or at any time during the study.~10. Conditions that preclude MR scanning~11. Conditions that preclude study drug administration~Exclusion criteria for healthy controls~All of the above and in addition:~1. Current use of psychotropic or potentially psychoactive prescription medication.~2. Major psychiatric disorder as determined by DSM-V (major depression, bipolar disorder, obsessive compulsive disorder, post-traumatic stress disorder, etc)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Levetiracetam (LEV) 500 mg (Type: EXPERIMENTAL): Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.

Based on this trial design, predict the completion outcome and termination type (if applicable).